An adapted F-test for homogeneity of variability in follow-on biological products.

In recent years, follow-on biological products (biosimilars) have received much attention from both the biotechnology industry and the regulatory agencies, especially after the passage of the 2010 healthcare reform bill. Unlike the traditional small-molecule drug products, the development of biological products is not only more complicated but also sensitive to small changes (both mean and variation) in procedure/environment during the manufacturing process because of some fundamental differences between drug products and biological products. A small change will have an impact on the quality of the product and consequently the treatment effect. Thus, in addition to the assessment of biosimilarity in average, it was suggested that biosimilarity in variability between biological products should be assessed. In this article, we propose an adapted F-test for homogeneity of variances to assess biosimilarity in variability. We study the performance and concordance of the proposed adapted F-test and compare it with probability-based method by extensive Monte Carlo simulations.

[1]  S. Roger Biosimilars: How similar or dissimilar are they? (Review Article) , 2006 .

[2]  S. Chow,et al.  Statistical Assessment of Biosimilar Products , 2009, Journal of biopharmaceutical statistics.

[3]  Shein-Chung Chow,et al.  Design and Analysis of Bioavailability and Bioequivalence Studies , 1994 .

[4]  Shein-Chung Chow,et al.  Statistical Test for Evaluation of Biosimilarity in Variability of Follow-On Biologics , 2010, Journal of biopharmaceutical statistics.

[5]  S. Chow Individual Bioequivalence—A Review of the FDA Draft Guidance , 1999 .

[6]  S. Chow,et al.  Design and Analysis of Bioavailability and Bioequivalence Studies, The Third Edition , 2008 .

[7]  S. Roger Biosimilars: how similar or dissimilar are they? , 2006, Nephrology.

[8]  E. Chi,et al.  A Comparison of Moment-Based and Probability-Based Criteria for Assessment of Follow-On Biologics , 2009, Journal of biopharmaceutical statistics.

[9]  Steven Kozlowski,et al.  The FDA's assessment of follow-on protein products: a historical perspective , 2007, Nature Reviews Drug Discovery.

[10]  S. Roger,et al.  Biosimilars: opportunity or cause for concern? , 2007, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[11]  Andrew R Fox Biosimilar Medicines—New Challenges for a New Class of Medicine , 2009, Journal of biopharmaceutical statistics.